Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 4.249
Filter
1.
An. Fac. Cienc. Méd. (Asunción) ; 55(2): 25-31, 20220801.
Article in Spanish | LILACS | ID: biblio-1380296

ABSTRACT

Introducción: El personal de salud constituye un grupo de riesgo para la infección por el virus de las hepatitis B. Objetivos: Evaluar la frecuencia de vacunación contra Hepatitis B en profesionales médicos y de enfermería de tres grandes centros hospitalarios del Departamento Central de Paraguay. Materiales y métodos: Estudio cuantitativo, observacional, descriptivo, de corte transversal. Se aplicó un cuestionario al personal médico y de enfermería en estudio, elaborado según trabajos afines. Resultados: Fueron encuestadas 1097 personas, siendo médicos 412 (37.6%) yersonal de enfermería 685 (62.4%). Se encontró un nivel de vacunación completa del 48.2% sobre el total de encuestados, 49.5% de los varones presentaron esquema completo y 47.7% de las mujeres. Según la profesión, el personal de enfermería tiene mejor acatamiento con 51% de vacunación completa contra 47% del personal médico. En el Hospital Central del Instituto de Previsión Social, casi un 62% tenía esquema completo, el Hospital de Clínicas alcanzó 40.9% y solamente 36.6% de los encuestados del Hospital Nacional de Itauguá tenían todas las dosis de vacuna anti-Hepatitis B. Para riesgo biológico bajo, el nivel de vacunación completa fue del 36.0%, alcanzó el 36.8% para riesgo moderado y 57.3% para los de alto riesgo de exposición. Conclusión: Ante la baja prevalencia de vacunación completa contra Hepatitis B en el personal de salud, esta debe mejorarse considerando el riesgo biológico de exposición. El equipo de control de infecciones y el Departamento de salud laboral deben llevar un registro de vacunación del personal y tener un plan de inmunizaciones obligatorio.


Introduction: Health care personnel constitute a risk group for hepatitis B virus infection. Objectives: To evaluate the frequency of vaccination against Hepatitis B in medical and nursing professionals of three large hospital centers in the Central Department of Paraguay. Materials and methods: Quantitative, observational, descriptive, cross-sectional, cross-sectional study. A questionnaire was administered to medical and nursing personnel included in the study, based on related studies. Results: A total of 1097 people were surveyed, 412 (37.6%) were physicians and 685 (62.4%) were nurses. In general, a complete vaccination level of 48.2% of the total respondents was reached, 49.5% of men had a complete vaccination schedule and 47.7% of women. According to profession, the nursing staff had a better compliance with complete vaccination with 51% versus 47% of the medical staff. In the Hospital Central del Instituto de Previsión Social almost 62% had a complete schedule, the Hospital de Clínicas reached 40.9% and only 36.6% of the respondents of the Hospital Nacional de Itauguá had all the doses of anti-Hepatitis B vaccine. For low biological risk, the level of complete vaccination was 36.0%, reaching 36.8% for moderate risk and 57.3% for those at high risk of exposure. Conclusion: The level of complete vaccination against Hepatitis B in health personnel was low and should be improved, taking into account the biological risk of exposure. The infection control team and the occupational health department should keep a record of staff vaccination and have a mandatory immunization plan for it.


Subject(s)
Hepatitis B , Hepatitis Viruses , Occupational Health , Immunization , Vaccination , Health Personnel , Hepatitis B Vaccines
2.
Buenos Aires; GCBA. Gerencia Operativa de Epidemiología; 8 jul. 2022. f:12 l:19 p. tab, graf.(Boletín Epidemiológico Semanal: Ciudad Autónoma de Buenos Aires, 7, 307).
Monography in Spanish | LILACS, InstitutionalDB, BINACIS, UNISALUD | ID: biblio-1391790

ABSTRACT

La hepatitis B es una infección vírica que afecta al hígado, puede dar lugar tanto a un cuadro agudo como a una enfermedad crónica, y se transmite por la vía sexual, vertical y parenteral. En este informe, se describe la situación mundial y nacional de esta patología, y su transmisión vertical, así como la caracterización de niños expuestos al virus durante el embarazo, nacidos en el Hospital Materno Infantil Ramón Sardá entre 2018 y 2021.


Subject(s)
Humans , Female , Pregnancy , Infant, Newborn , Infectious Disease Transmission, Vertical/prevention & control , Infectious Disease Transmission, Vertical/statistics & numerical data , Hepatitis B/transmission , Hepatitis B/epidemiology , Epidemiological Monitoring , Infant, Newborn, Diseases/epidemiology
3.
Lima; Perú. Ministerio de Salud. Centro Nacional de Epidemiología, Prevención y Control de Enfermedades; 1 ed; Jun. 2022. 1158-93 p. ilus.(Boletín Epidemiológico, 31, SE-24).
Monography in Spanish | LILACS, LIPECS, MINSAPERU | ID: biblio-1379438

ABSTRACT

Luego del llamado realizado por la Asamblea Mundial de la Salud en el 2014, para que los países implementen medidas que garanticen y fortalezcan la vigilancia, la prevención, el acceso al tratamiento y el control de las hepatitis virales en todos los países, nos preguntamos ¿Qué avances hemos tenido? En el 2016, con la finalidad de fortalecer la atención del recién nacido y seguimiento del niño expuesto a madres con hepatitis B en el Perú, se aprobó el documento técnico "Plan Nacional para la Eliminación de la Transmisión Materno Infantil del VIH, Sífilis, y Hepatitis B, en el Perú 2017-2021", en la cual se establece como objetivos acciones para reducir la transmisión infantil de hepatitis B a un 5%. En referido documento se identifican limitantes como: el bajo porcentaje de niñas y niños expuestos tamizados, pérdida del seguimiento de gestantes y de niños y niñas expuestos, y la débil coordinación entre los servicios de la salud.


Subject(s)
Syphilis , Epidemiologic Studies , Epidemiologic Measurements , Aftercare , Epidemiological Monitoring , Health Services Accessibility , Hepatitis B
4.
Poblac. salud mesoam ; 19(2)jun. 2022.
Article in Spanish | LILACS-Express | LILACS, SaludCR | ID: biblio-1386952

ABSTRACT

Resumen Introducción: se busca cuantificar los retornos de la inversión asociados a una intervención en el sistema público de salud de un municipio de la Provincia de Buenos Aires, Argentina, consistente en el fortalecimiento de la estrategia denominada Eliminación de la Transmisión Maternoinfantil de la Infección por VIH, Sífilis, enfermedad de Chagas Congénita e Infección Perinatal por Hepatitis B (ETMI-PLUS). Metodología: el estudio (cuantitativo) se basa en la metodología de Retorno Social de la Inversión (RSI). Se establecieron definiciones ad-hoc para la medición de los retornos sobre la base de los datos disponibles provenientes de diversas fuentes: información primaria de la Secretaría de Salud del MAB; tasas de transmisión congénita de cada enfermedad notificados al Sistema Nacional de Vigilancia de Salud; presupuestos detallados de los recursos asignados al proyecto por parte de la Fundación Mundo Sano y costos de tratamientos e insumos de nomencladores oficiales. Resultados: por cada peso invertido para reforzar la ETMI-PLUS en el MAB, se obtuvo un retorno de casi 4 pesos, gracias a las mejoras en la eliminación vertical de las cuatro enfermedades y al descenso de las complicaciones cardiacas en las mujeres embarazadas diagnosticadas con chagas y tratadas oportunamente. Conclusiones: estos resultados sugieren la existencia de una relación retorno-inversión favorable, analizada bajo una perspectiva conservadora, ya que, se incluyen exclusivamente los ahorros para el sistema de salud y se excluyen otras dimensiones de los retornos vinculadas con las mejoras en los resultados alcanzados.


Abstract Introduction: we seek to quantify the returns on investment associated with an intervention in the public health system of a Municipality of the Province of Buenos Aires, Argentina. This intervention consists of strengthening the strategy for the Elimination of Mother-to-Child Transmission of HIV Infection, Syphilis, Congenital Chagas Disease and Perinatal Hepatitis B Infection, a strategy called ETMI-PLUS. Methodology: the study (quantitative) is based on the Social Return on Investment (RSI) methodology. Ad-hoc definitions are established for the measurement of returns based on the information available from various sources: primary information from the Ministry of Health of the MAB; rates of congenital transmission of each disease reported to the National Health Surveillance System; detailed budgets of the resources assigned to the project by Fundación Mundo Sano and costs of treatments and supplies from official nomenclators. Results: for each argentinean peso invested in strengthening the ETMI-PLUS in the MAB, a return of almost 4 pesos would have been obtained thanks to the improvements in the vertical elimination of the 4 diseases and the reduction of cardiac complications in pregnant women.Conclusions: these results suggest the existence of a return / investment relationship favorable to the intervention, analyzed under a conservative analysis since savings for the health system are exclusively included and other dimensions of returns associated with improvements in results are excluded.


Subject(s)
Humans , Syphilis/prevention & control , HIV , Chagas Disease/prevention & control , Hepatitis B/prevention & control , Argentina , Infectious Disease Transmission, Vertical/prevention & control
5.
Rev. colomb. gastroenterol ; 37(2): 163-172, Jan.-June 2022. tab, graf
Article in English, Spanish | LILACS | ID: biblio-1394945

ABSTRACT

Abstract Introduction: Hepatocellular carcinoma (HCC) is the most frequent malignant primary liver tumor globally. In 2018, it ranked sixth and represented the fourth cause of death from cancer; the five-year overall survival is 18 %. Most cases of HCC develop in patients with cirrhosis of any etiology, especially because of hepatitis B and C viruses, alcohol, and recently nonalcoholic steatohepatitis (NASH). Aim: To analyze the clinical characteristics, diagnostic methods, treatments, prognostic variables, and survival. Materials and methods: This retrospective descriptive study was conducted on a cohort of patients diagnosed with cirrhosis and treated between January 2011 and December 2020 at a health care center in Bogotá. The diagnosis of HCC was confirmed radiologically or by biopsy. We analyzed the information descriptively with absolute frequency measures in the case of categorical variables. For continuous variables, the information was summarized with measures of central tendency (mean or median) and their relevant measures of dispersion. Results: We included 152 patients diagnosed with HCC, with a mean age of 69.4 years; 51.3 % were men. The leading cause of HCC was nonalcoholic fatty liver disease (NAFLD), which accounted for almost a third of cases (32 %); other causes were alcohol (15 %) and hepatitis C virus (14 %). The median manifestation of the tumor was two nodules with a size close to 4 cm. Besides, 35 % of patients had a BCLC (Barcelona Clinic Liver Cancer) stage with curative options, and 25 % received curative treatment options. The first-line systemic therapy used in this cohort was sorafenib®, used in 35 patients (33.7 %). Survival curves showed that women, Child-Pugh class A, and BCLC stage 0 had higher median survival. Multivariate analysis showed a higher risk of death for males (hazard ratio [HR]: 2.16; confidence interval [CI]: 1.24-3.76), Child-Pugh class B (HR: 2.14; CI 1.16-3.95), and Child-Pugh class C (HR: 7.52; CI 2.88-19.57). Conclusions: NAFLD is the leading cause of HCC in this cohort. A third of patients are diagnosed in early BCLC stages with a curative treatment option, and 25 % are treated with curative therapies. Sorafenib was the first-line therapy in advanced HCC. Overall survival after diagnosis of HCC remains low, being necessary to join forces in the follow-up of patients with cirrhosis to improve these outcomes.


Resumen Introducción: el hepatocarcinoma (HCC) es el tumor hepático primario maligno más frecuente en el mundo: en 2018 ocupó la sexta posición y representó la cuarta causa de muerte por cáncer; la supervivencia global a 5 años es del 18 %. La mayoría de los casos de HCC se desarrolla en pacientes con cirrosis de cualquier etiología, especialmente por virus de la hepatitis B y C, alcohol y, recientemente, por la esteatohepatitis no alcohólica (NASH). Objetivo: analizar las características clínicas, métodos de diagnóstico, tratamientos, variables pronósticas y supervivencia. Metodología: estudio descriptivo retrospectivo de una cohorte de pacientes con diagnóstico de cirrosis atendidos entre enero de 2011 y diciembre de 2020 en un centro de atención médica de Bogotá, con diagnóstico de HCC confirmado radiológicamente o por biopsia. La información se analizó de forma descriptiva con medidas de frecuencia absoluta en el caso de las variables categóricas; para las variables continuas se resumió la información con medidas de tendencia central (media o medianas) y su respectiva medida de dispersión. Resultados: se incluyeron 152 pacientes diagnosticados con HCC, con edad promedio de 69,4 años, 51,3 % eran hombres. La principal causa de HCC fue el hígado graso no alcohólico (NAFLD), que representó casi una tercera parte de los casos (32 %); otras causas fueron el alcohol (15 %) y el virus de la hepatitis C (14 %). La mediana de presentación del tumor fue de 2 nódulos con un tamaño cercano a 4 cm. El 35 % de los pacientes tenía un estadio BCLC (Barcelona Clinic Liver Cancer) con opciones curativas y el 25 % de los pacientes recibió opciones curativas de tratamiento. La terapia sistémica de primera línea utilizada en esta cohorte fue el sorafenib®, que se utilizó en 35 pacientes (33,7 %). Las curvas de supervivencia mostraron que las mujeres, el estadio Child-Pugh A y el estadio BCLC 0 presentaron mayores medianas de supervivencia. El análisis multivariado evidenció un mayor riesgo de muerte al ser hombre (Hazard ratio [HR]: 2,16; intervalo de confianza [IC]: 1,24 a 3,76), estar en los estadios Child-Pugh B (HR: 2,14; IC: 1,16 a 3,95) y Child-Pugh C (HR: 7,52; IC: 2,88 a 19,57). Conclusiones: el NAFLD es la principal causa de HCC en la presente cohorte, una tercera parte de los pacientes se diagnostica en estadios BCLC tempranos con opción curativa de tratamiento, y un 25 % se trata con terapias curativas. El sorafenib fue la terapia de primera línea en HCC avanzado. La supervivencia global luego del diagnóstico de HCC sigue siendo baja, y es necesario aunar esfuerzos en el seguimiento de los pacientes con cirrosis para mejorar estos resultados.


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Aged, 80 and over , Therapeutics , Hepatitis B virus , Carcinoma, Hepatocellular , Diagnosis , Non-alcoholic Fatty Liver Disease , Sorafenib , Hepatitis B , Liver Neoplasms , Patients , Survival , Confidence Intervals , Causality , Multivariate Analysis , Central Trend Measures , Neoplasms
6.
Acta sci., Health sci ; 44: e56401, Jan. 14, 2022.
Article in English | LILACS | ID: biblio-1367453

ABSTRACT

Blood-borne viruses, includingthe human immunodeficiency virus and hepatitis B virus, have certain common epidemiological characteristics and these viruses infect millions of people worldwide. This study aimed to determine the job satisfaction and the level of knowledge and practices regarding infectious diseases of employees working as hairdressers and barbers.This descriptive and cross-sectional study comprised 1200 hairdressers and barbers. The study sample comprised 628 people who consented to participate in the study. The mean age of the participants who participated in the study was 28, 13 ± 6. 9 years. The mean job satisfaction score of the participants was 3.85 ± 0.58. The job satisfaction score was found to be higher among those with sufficient knowledge of hepatitis B (p < 0.005). Employees should be provided performance trainings to achieve job satisfaction. It is recommended that employees be encouraged to wear gloves and gowns to protect their health and prevent contamination.


Subject(s)
Humans , Male , Female , Adult , Barbering/instrumentation , HIV , Knowledge , Beauty and Aesthetics Centers , Hepatitis B/epidemiology , Hepatitis B/virology , Hepatitis B virus , Communicable Diseases/transmission , Communicable Diseases/epidemiology , Occupational Health/ethnology , Acquired Immunodeficiency Syndrome/epidemiology , Acquired Immunodeficiency Syndrome/virology , Personal Protective Equipment/supply & distribution , Personal Protective Equipment/virology , Job Satisfaction , Occupational Groups
7.
Article in English | LILACS | ID: biblio-1381653

ABSTRACT

Introduction: The prevention of vertical transmission of sexually transmitted diseases is the object of research by several authors, who reinforce the importance of knowing the serological status of a woman's sexual partner. Objective: To evaluate the prevalence and serodiscordance of HIV, hepatitis B, hepatitis C, and syphilis infections among women admitted to a maternity hospital in southern Brazil and their partners. Methods: 350 women and their partners were interviewed in a service-based cross-sectional study conducted from August 16 to November 23, 2018. Results: 4.0% of the women and 4.3% of the men had one of the infections studied. Among women, 2.0% already knew they were HIV positive, 2.0% had a positive rapid test for syphilis and there was no positive result for hepatitis B or C. A total of 299 (85.4%) partners were located. Of these, 293 (98.0%) agreed to answer the study questionnaire. Of all men interviewed, 281 (95.9%) agreed to undergo an rapid test. Among men, 1.4% already knew they were HIV positive and 0.4% had chronic hepatitis B disease. There was a similar percentage of men with a positive rapid test for syphilis and hepatitis C (1.4%). Regarding couples, 6.8% had some positive test. Most of the positive test subjects were in a serodiscordant relationship (16 serodiscordant couples and 3 positive concordant couples). Conclusion: These results reinforce the importance of testing men to prevent the infection of a negative partner and the vertical transmission of sexually transmitted infections. The high acceptance, by men, to undergo an rapid test at the time of the woman's hospitalization demonstrated the viability of this strategy in the maternity ward.


Introdução: A prevenção da transmissão vertical de doenças sexualmente transmissíveis é objeto de pesquisa de diversos autores, os quais reforçam a importância do status sorológico do parceiro sexual da mulher. Objetivo: Avaliar a prevalência e a sorodiscordância de infecções por HIV, hepatite B, hepatite C e sífilis em mulheres internadas em uma maternidade localizada no Sul do Brasil e seus parceiros. Métodos: Foram entrevistadas 350 mulheres e seus parceiros em um estudo transversal de base de serviço realizado de 16 de agosto a 23 de novembro de 2018. Resultados: Do grupo consultado, 4,0% das mulheres e 4,3% dos homens apresentaram alguma das infecções estudadas. Entre as mulheres, 2% já sabiam ser HIV positivas e 2% apresentaram teste rápido positivo para sífilis. Para hepatite B ou C, não se registrou nenhum resultado positivo. Foram localizados 299 (85,4%) companheiros, destes, 293 (98,0%) aceitaram responder ao questionário do estudo. Do total de homens entrevistados, 281 (95,9%) concordaram em se submeter aos testes rápidos, entre eles, 1,4% já sabiam ser HIV positivos, 0,4% eram portadores crônicos de hepatite B e 1,4% apresentaram testes rápidos positivos para sífilis e hepatite C. Em relação aos casais, 6,8% possuíam algum teste positivo, a maioria (16) era formada de indivíduos sorodiscordantes e 3 de concordantes positivos. Conclusão: Esses resultados reforçam a importância da testagem masculina com a intenção de evitar a infecção do cônjuge negativo e a transmissão vertical das infecções sexualmente transmissíveis. A alta aceitação masculina de se submeter ao teste rápido durante a internação da mulher demonstrou a viabilidade dessa estratégia de testagem na maternidade.


Subject(s)
Humans , Women , Sexually Transmitted Diseases , Infectious Disease Transmission, Vertical , Syphilis , HIV , Hepatitis C , Hepatitis B
8.
Rev. bras. epidemiol ; 25: e220004, 2022. tab, graf
Article in English | LILACS | ID: biblio-1360903

ABSTRACT

ABSTRACT: Objective: This study aimed to describe and analyze the temporal and spatial distribution of deaths due to hepatocellular carcinoma (HCC) associated with hepatitis B (HBV) and C viruses (HCV) in the state of São Paulo. Methods: This is an ecological study of HCC deaths associated with HBV and HCV in the state of São Paulo, from 2009 to 2017, with data from the Mortality Information System (SIM). The temporal trend was analyzed by linear regression with Prais-Winsten estimation. Deaths were described according to sociodemographic characteristics by means of absolute and relative frequencies and were spatially distributed according to the regional health department. Results: It is found that 26.3% of deaths due to HCC were associated with HBV or HCV. A higher proportion of deaths due to HCC associated with HCV was observed (22.2%) when compared to HBV (3.9%). The mortality rate due to HCC associated with HBV showed a downward trend, and the mortality rate due to HCC associated with HCV showed a steady trend. Deaths of males, white individuals, those who aged from 50 to 59 years, and those who had 8-11 years of schooling predominated. Spatial analysis revealed a heterogeneous distribution of deaths in the state of São Paulo. Conclusions: The downward trend in mortality rates due to HCC associated with HBV shows an important advance in the disease control. However, the mortality rate due to HCC associated with HCV has remained stable throughout the study period. The spatial distribution of deaths may contribute to raise hypotheses for deeper knowledge of these diseases in the regions.


RESUMO: Objetivos: Este estudo tem como objetivo descrever e analisar a distribuição temporal e espacial dos óbitos por carcinoma hepatocelular associados às hepatites virais B e C no estado de São Paulo. Métodos: Estudo ecológico dos óbitos por carcinoma hepatocelular associados a hepatites virais B e hepatites virais C no estado de São Paulo, de 2009 a 2017, com dados do Sistema de Informação sobre Mortalidade. A tendência temporal foi analisada por regressão linear, com método de Prais-Winsten. Os óbitos foram descritos segundo as características sociodemográficas, por meio de frequências absolutas e relativas, e foram espacialmente distribuídos segundo departamento regional de saúde. Resultados: Dos óbitos por carcinoma hepatocelular, 26,3% foram associados a hepatites virais B ou hepatites virais C. Observou-se maior proporção de óbitos por carcinoma hepatocelular associado a hepatites virais C (22,2%) quando comparada àquela associada a hepatites virais B (3,9%). A taxa de mortalidade por carcinoma hepatocelular associado a hepatites virais B apresentou tendência de queda, no entanto a taxa de mortalidade por carcinoma hepatocelular associado a hepatites virais C apresentou tendência estacionária. Predominaram óbitos de pacientes do sexo masculino, de cor branca, de 50-59 anos e com oito a 11 anos de estudo. A análise espacial revelou distribuição heterogênea dos óbitos no estado de São Paulo. Conclusão: A tendência de queda nas taxas de mortalidade por carcinoma hepatocelular associado a hepatites virais B revela um importante avanço no controle do agravo. Entretanto, a taxa de mortalidade por carcinoma hepatocelular associado a hepatites virais C vem-se mantendo estável ao longo do período estudado. A distribuição espacial dos óbitos pode contribuir para levantar hipóteses com vistas ao conhecimento mais aprofundado desses agravos nas regiões.


Subject(s)
Humans , Male , Middle Aged , Viruses , Carcinoma, Hepatocellular/complications , Hepatitis B/complications , Liver Neoplasms , Brazil/epidemiology
9.
Ann. afr. méd. (En ligne) ; 15(4): 1-9, 2022. figures, tables
Article in French | AIM | ID: biblio-1398384

ABSTRACT

Contexte et objectifs. Les hépatites virales chroniques constituent un problème de santé publique en Côte-d'Ivoire. Très peu de malades accèdent au traitement en raison des coûts élevés du bilan et du traitement. L'objectif de la présente étude était d'évaluer les coûts du bilan et du traitement des hépatites virales chroniques. Méthodes. Il s'agissait d'une étude observationnelle transversale analytique réalisée, du 1er mars 2019 au 31 juillet 2019, en consultation d'hépato-gastroentérologie du CHU de Yopougon. Les variables étudiées étaient les paramètres sociodémographiques et économiques. Résultats. Au total, 136 patients (hommes 53, 6 %, âge moyen de 42 ans ± 12,2) ont été inclus. Plus de la moitié des patients (63,3 %) avaient un revenu mensuel n'excédant pas 490.39 USD. Le coût du bilan initial était de 223.13 USD et de 351.14 USD respectivement, pour l'hépatite virale B et C. Le ténofovir et l'interféron pégylé étaient gratuits. Le traitement par sofosbuvir + velpastavir coûtait 593.37 USD. Le bilan de suivi annuel était estimé à 237.02 USD pour l'hépatite virale B, 225.58 USD pour l'hépatite virale C. Conclusion. Le bilan et le traitement des hépatites virales chroniques ont un coût prohibitif pour les patients malgré la couverture maladie universelle.


Context and objectives. Chronic viral hepatitis is a public health problem in Côte-d'Ivoire. A significant number of patients have little access to treatment due to the high costs of assessment and treatment. The objective of our study was to evaluate the costs of assessments and treatment of chronic viral hepatitis. Methods. This was an analytical cross-sectional observational study from March 1, 2019 to July 31, 2019 in the HepatoGastroenterology Consultation Service at the Yopougon University Hospital. The variables studied were socio-demographic and economic parameters. Results. 136 patients (men 53.6 %, average age 42 ± 12.2 years) were included. More than half of the patients (63.3 %) had a monthly income not exceeding 490.39 USD. The cost of the initial assessment was 223.13 USD and 351.14 USD for viral hepatitis B and C, respectively. Tenofovir and pegylated interferon were free of charge. Treatment with sofosbuvir + velpastavir cost 593.37 USD. The annual follow-up assessment was estimated at 237.02 USD for viral hepatitis B and 225.58 USD for viral hepatitis C. Conclusion. The assessment and treatment of chronic viral hepatitis have a cost that remains high for patients despite the universal health coverage.


Subject(s)
Humans , Male , Female , Health Care Costs , Disease Management , Hepatitis C, Chronic , Diagnosis , Hepatitis B , Hepatitis, Viral, Human
10.
Ann. afr. méd. (En ligne) ; 15(4): 1-8, 2022. tables
Article in French | AIM | ID: biblio-1398514

ABSTRACT

Contexte & objectif. L'hépatite virale B (HVB) par son évolution peut déboucher vers la guérison ou vers une forme chronique qui est très peu documentée chez les donneurs bénévoles de sang (DBS). L'objectif de la présente étude était de déterminer la prévalence de l'HVB chronique. Méthodes. L'étude réalisée au Centre National de Transfusion Sanguine de Bangui était rétrospective et portait sur les données de contrôle sérologique des DBS de Bimbo et de Bangui, capitale de la République centrafricaine (RCA). L'échantillonnage exhaustif concerne la période de juillet 2013 à décembre 2019. Le DBS est porteur d'une infection chronique si l'antigène de surface de l'HVB persiste pendant plus de six mois. Le test de Chi carré de Pearson au seuil de 5 % et l'odd ratio (OR) ont été utilisés comme test d'association. Résultats. Les données de contrôle sérologique de 702 DBS âgés de 18 à 62 ans ont été analysées. Le sexe masculin était prépondérant (n=598). La prévalence de l'HVB chronique était de 70,5 %. Cette prévalence était plus élevée chez les DBS de 25 à 34 ans (30,4 %), les hommes (58,8 %) et les DBS qui résident à Bangui (61,2 %). La forme chronique était significativement associée au jeune âge (18 à 44 ans) et au sexe masculin (p< 0,05). La coïnfection par le VIH et l'hépatite C était retrouvée dans 5,5 % des cas (39/702). Conclusion. La prévalence de l'HVB chronique est très élevée chez les DBS de Bangui et Bimbo. La forme chronique était significativement associée à l'âge et au sexe. La gratuité de la charge virale et du traitement antiviral sont des perspectives à mettre en œuvre


Context and objective. Viral hepatitis B (VHB) by its evolution can lead to recovery or to a chronic form. This chronic form, a source of new contaminations, is not documented among voluntary blood donors (VBD) in Bangui and Bimbo. The present study aimed to determine the prevalence of chronic VHB among VBD in the two cities in the Central African Republic (CAR). Methods. The study carried out at the Bangui National Blood Transfusion Center was retrospective and focused on serological control data from VBD from Bangui, capital of CAR and Bimbo. The exhaustive sampling is from July 2013 to December 2019. A VBD carries a chronic infection if the VHB surface antigen persists for more than six months. Results. Serological control data from 702 VBD aged 18 to 62 years were analyzed. Male sex predominated at inclusion (n = 598). The prevalence of chronic VHB was 70.5 %. This prevalence was higher among young VBD aged 25 to 34 years (30.4 %), the male gender (58.4 %) and VBD residing in Bangui (61.2 %). The chronic form was significantly associated with young age (18 to 44 years) and male sex (p< 5%). Co-infection with HIV and hepatitis C was found in 5.5 % of cases (39/702). Conclusion. The prevalence of chronic VHB is very high in VBD from Bangui and Bimbo. The chronic form was significantly associated with age and sex. Free viral load and antiviral treatment are prospects to be implemented.


Subject(s)
Humans , Male , Female , Adolescent , Adult , Middle Aged , Blood Donors , HIV Infections , Hepatitis B, Chronic , Hepatitis B , Coinfection
11.
Afr. health sci. (Online) ; 22(2): 107-115, 2022. figures, tables
Article in English | AIM | ID: biblio-1400304

ABSTRACT

Background: Hepatitis B virus infection is one of the leading causes of liver diseases which occurs worldwide particularly in developing countries. It is often caused by prenatal transmission from mother to child or household transmission from a close contact during early childhood. It causes different complications like; jaundice, induces premature labor, and prematurity. Objective: The aim of this study was to estimate the sero-prevalence of hepatitis B virus surface antigen and associated factors among women of reproductive age in Bench Maji Zone, South West Ethiopia. Methods: A community-based cross-sectional study was conducted from December 15th, 2016 to February 15th, 2017. Multistage sampling technique was applied to select study participants. Logistic regression analysis was applied and p-values < 0.05 was used to see the significant association between dependent and independent variables. Results: A total of 330 participants were included in this study yielding 98.8% response rate. The sero-prevalence of HBsAg among women of reproductive age was 28(8.5%). Having multiple sexual partners (AOR = 18.73, 95% CI =3.65, 96.21) history of unprotected sex (AOR = 9.39, 95% CI =1.64, 53.77) were found to be significantly associated with sero-prevalence of HBV. Conclusions: The sero-prevalence of HBV infection among women of reproductive age was highly endemic. Hence, behavioral education and communication programs focusing on reduction of risky sexual behaviors should be designed to reduce HBV infection.


Subject(s)
Humans , Male , Female , Hepatitis B virus , Hepatitis B , Hepatitis B Surface Antigens , Obstetric Labor, Premature , Jaundice
12.
African Health Sciences ; 22(1): 496-503, March 2022. Figures, Tables
Article in English | AIM | ID: biblio-1400684

ABSTRACT

Background: Hepatitis B virus infection is one of the leading causes of liver diseases which occurs worldwide particularly in developing countries. It is often caused by prenatal transmission from mother to child or household transmission from a close contact during early childhood. It causes different complications like; jaundice, induces premature labor, and prematurity. Objective: The aim of this study was to estimate the Sero-prevalence of hepatitis B virus surface antigen and associated factors among women of reproductive age in Bench Maji Zone, South West Ethiopia. Methods: A community-based cross-sectional study was conducted from December 15th, 2016, to February 15th, 2017. Multistage sampling technique was applied to select study participants. Logistic regression analysis was applied and p-values < 0.05 was used to see the significant association between dependent and independent variables. Results: A total of 330 participants were included in this study yielding 98.8% response rate. The Sero-prevalence of hbsag among women of reproductive age was 28(8.5%). Having multiple sexual partners (AOR = 18.73, 95% CI = [3.65, 96.21) history of unprotected sex (AOR = 9.39, 95% CI = [1.64, 53.77) were found to be significantly associated with Sero-prevalence of HBV. Conclusions: The Sero-prevalence of HBV infection among women of reproductive age was highly endemic. Hence, behavioral education and communication programs focusing on reduction of risky sexual behaviors should be designed to reduce HBV infection


Subject(s)
Viruses , Hepatitis B , Infections , Liver Diseases , Antigens, Surface , Reproductive Control Agents , Women , Ethiopia
13.
Article in Chinese | WPRIM | ID: wpr-936146

ABSTRACT

OBJECTIVE@#To evaluate the effects of hepatitis B virus (HBV) on helper T lymphocytes 17 (Th17), regulatory T lymphocyte (Treg) and Th17/Treg ratio in chronic hepatitis B patients in different alanine aminetransferase (ALT) stages.@*METHODS@#In the study, 336 chronic hepatitis B patients in the first hospital of Lanzhou University were analyzed. The hepatitis B antigen antibody parameters were measured by chemiluminescence immunoassay analyzer, the liver function parameters were measured by automatic biochemical analyzer, the HBV loads were measured by quantitative PCR, Th17, Treg and Th17/Treg ratios were detected by flow cytometry. Among them, 111 cases (ALT < 40 U/L) of ALT were normal hepatitis B, 108 cases of chronic hepatitis B with ALT above normal upper limit and < 2 times higher (40 U/L≤ALT < 80 U/L), and 117 cases of chronic hepatitis B with ALT above 2 times normal upper limit (80 U/L≤ALT). According to the viral load, they were divided into low replication group with HBV DNA < 4.0 lg copies/mL, medium replication group with 4.0 lg copies/mL≤HBV DNA < 6.0 lg copies/mL and high replication group with HBV DNA ≥ 6.0 lg copies / mL. Dunnett T3 variance analysis were used to analyze the effects of HBV on Th17, Treg and Th17/Treg ratio in the chronic hepatitis B patients in different ALT stages. The changes of virological and immunological indexes before and after treatment were observed for 24 weeks of antiviral therapy in the hepatitis B patients with ALT≥double upper limit of normal group.@*RESULTS@#In the ALT normal group, different virus load HBV had minor effects on Th17, Treg and Th17/Treg ratio. In the ALT≥2 times upper limit of normal group, with the virus load increased, Th17 (3.18%±0.79% in low replication group, 3.78%±0.92% in medium replication group and 4.57%±1.15% in high replication group), Treg cells (5.52%±1.58% in low replication group, 5.89%±1.84% in medium replication group and 6.37%±2.35% in high replication group) and their ratio Th17/Treg (0.57±0.25 in low replication group, 0.65±0.29 in medium replication group and 0.73±0.36 in high replication group) were significantly increased (P < 0.05). After entecavir treatment 24 weeks, the patient' s HBV-DNA decreased significantly, Th17 (3.89%±1.02% vs. 2.06%±0.46%), Treg (6.02%±2.03% vs. 5.06%±1.25%), Th17/Treg ratio (0.65±0.28 vs. 0.41±0.14) decreased significantly (P < 0.05).@*CONCLUSION@#Investigation on the effects of HBV on Th17 and Treg cells and their ratios in different ALT states can clarify the effects of HBV on the body from the immunological perspective and can further understand the ALT grouping for antiviral treatment theoretical significance, which is helpful for clinical treatment.


Subject(s)
Alanine/therapeutic use , Alanine Transaminase/therapeutic use , Antiviral Agents/therapeutic use , DNA, Viral/therapeutic use , Hepatitis B/drug therapy , Hepatitis B virus/genetics , Hepatitis B, Chronic/drug therapy , Humans , T-Lymphocytes, Regulatory
14.
Chinese Journal of Hepatology ; (12): 402-406, 2022.
Article in Chinese | WPRIM | ID: wpr-935958

ABSTRACT

Objective: To quantitatively evaluate myocardial work in patients with hepatitis B cirrhosis by using left ventricular pressure-strain loop. Methods: 70 cases with hepatitis B cirrhosis who were hospitalized in Henan Provincial People's Hospital from March to December 2020 were selected as the study group. Patients were divided into three subgroups according to the Child-Pugh score of liver cirrhosis (Child-Pugh class A, B, and C groups: 25, 25, and 20 patients, respectively). At the same time, 25 healthy volunteers were included as the control group. Global longitudinal strain (GLS), global myocardial work index (GWI), global work efficiency (GWE), global constructive work (GCW), and global wasted work (GWW) were obtained by applying pressure-strain loops. The differences were analyzed and compared among the four groups parameters. Results: Compared with the control group, the Child-Pugh class A group had decreased GLS, while Child-Pugh class B and C had decreased GLS, GWI, GWE, GCW, and increased GWW, and the differences were statistically significant (P<0.05). Compared with Child-Pugh class A group, Child-Pugh class B group had decreased GLS, GWE, and increased GWW, while Child-Pugh class C group had decreased GLS,GWI, GWE, GCW, and increased GWW, and the differences were statistically significant (P<0.05). Compared with Child-Pugh class B group, Child-Pugh class C group had decreased GLS, GWI, GWE, GCW, and increased GWW, and the differences were statistically significant (P<0.05). Conclusion: The pressure-strain loop can detect early myocardial dysfunction, and has a certain value in the diagnosis, treatment and prognosis evaluation of myocardial function changes in patients with hepatitis B cirrhosis.


Subject(s)
Hepatitis B , Humans , Liver Cirrhosis , Myocardium , Stroke Volume , Ventricular Function, Left
15.
Chinese Journal of Hepatology ; (12): 309-315, 2022.
Article in Chinese | WPRIM | ID: wpr-935943

ABSTRACT

Objective: To explore the clinical value of von Willebrand Factor (vWF) and VITRO score (vWF:Ag/platelet count) in assessing disease progression in patients with HBV infection. Methods: Randomly collect relevant clinical data of 308 patients with HBV infection (including 154 cases of chronic hepatitis B, 66 cases of hepatitis B cirrhosis in compensatory period, 88 cases of hepatitis B cirrhosis in decompensated period) from December 1, 2018 to January 5, 2021 in the Second Affiliated Hospital of Chongqing Medical University. The vWF values are measured by a uniform optical method, and all data are included using a uniform standard. Analyze the difference and significance of plasma vWF level and VITRO score in chronic hepatitis B, hepatitis B cirrhosis in the compensatory phase and decompensated phase. Results: The plasma vWF level and VITRO score of the chronic hepatitis B group were (139.47±76.44) and (0.86±0.8), respectively, and the hepatitis B cirrhosis compensated group was (164.95±67.12 and 1.44±1.14), respectively. Hepatitis cirrhosis decompensated group were (317.48±103.32 and 6.81±4.98), respectively; plasma vWF level and VITRO score increased with the progression of HBV infection, and the difference was statistically significant (F=133.669,P=0.000F=137.598,P=0.000).The plasma vWF level and VITRO score in patients with hepatitis B cirrhosis were (185.65±85.07 and 2.3±2.37) in the Child-Pugh A group, (304.74±105.81 and 6.37±5.19) in the B grade group, and (369.48±73.238.28±5.38) in the C grade group; plasma vWF level and VITRO score in patients with hepatitis B cirrhosis increased with the increase of Child-Pugh grade, and the difference was statistically significant (F=60.236, P=0.000F=32.854, P=0.000). The area under the curve (AUC) of plasma vWF level and VITRO score for diagnosing the decompensated stage of hepatitis B cirrhosis were 0.897 [95% confidence interval (CI): 0.855-0.940, P<0.01], 0.949 [95% CI: 0.916-0.982, P<0.01). When the vWF level and VITRO score were taken as cut-off values of 238.5% and 1.65, respectively, the sensitivity of diagnosing the decompensated stage of hepatitis B cirrhosis was 79.5% and 94.3%, the specificity was 92.3% and 87.7%, and the positive predictive value was 80.5% and 94.3%, the negative predictive value was 91.9% and 97.5%, and the diagnostic accuracy was 88.6% and 89.3%. Among the patients with decompensated hepatitis B cirrhosis, the level of vWF in the group with gastrointestinal bleeding (367.24±68.29)% was significantly higher than that in the group without gastrointestinal bleeding (286.15±109.69)%, and the difference was statistically significant (P<0.001) The VITRO score of the group with gastrointestinal bleeding (9.12±5.4) was significantly higher than that of the group without gastrointestinal bleeding (5.36±4.13), and the difference was statistically significant (P<0.01). The vWF level in the spontaneous peritonitis group was (341.73±87.92)% higher than that in the non-spontaneous peritonitis group (296.32±111.74)%, and the difference was statistically significant (P<0.05). There was no statistical difference in VITRO score between the two groups. significance. Conclusion: Plasma vWF level and VITRO score can evaluate the progression of liver disease and the degree of decompensation of liver cirrhosis in patients with HBV infection, and have a predictive effect on various complications after decompensation of liver cirrhosis, and have certain guiding significance for early intervention measures.


Subject(s)
Disease Progression , Gastrointestinal Hemorrhage/etiology , Hepatitis B/complications , Hepatitis B virus , Hepatitis B, Chronic/diagnosis , Humans , Liver Cirrhosis/virology , Peritonitis/complications , von Willebrand Factor/analysis
16.
Chinese Journal of Hepatology ; (12): 99-102, 2022.
Article in Chinese | WPRIM | ID: wpr-935916

ABSTRACT

Covalently closed circular DNA (cccDNA) of hepatitis B virus (HBV) is the template for HBV replication. Currently, there is a lack of therapeutic drugs that directly target cccDNA. Therefore, blocking cccDNA supplements as fast as possible and reducing the existing cccDNA is the key to achieving a complete cure of chronic hepatitis B. Previous studies have suggested that cccDNA had a long half-life, but a recent study showed that it only took a few months to update cycle of cccDNA pool, and its number was much less than previously predicted. In the future, with the advent of new antiviral drugs that can completely inhibit HBV replication, it is expected that the cccDNA pool will be completely cleared due to its supplement complete blockade, so as to achieve virological cure of chronic hepatitis B.


Subject(s)
Antiviral Agents/therapeutic use , DNA, Circular/genetics , DNA, Viral , Half-Life , Hepatitis B/drug therapy , Hepatitis B virus/genetics , Hepatitis B, Chronic/drug therapy , Humans , Virus Replication
17.
Chinese Journal of Hepatology ; (12): 52-56, 2022.
Article in Chinese | WPRIM | ID: wpr-935907

ABSTRACT

Objective: To explore the role of nonalcoholic fatty liver disease (NAFLD) in the development of hepatocellular carcinoma (HCC) in patients with prior hepatitis B virus infection (HBsAg-negative and anti-HBC-positive). Methods: 1605 hospitalized patients who were first diagnosed with HCC at Nanfang Hospital between 2015 to 2017 were retrospectively studied. Patients who developed HCC on the basis of active HBV infection (HBsAg-positive, anti-HBc positive) were used as control. Multivariate logistic regression model was used to analyze the relationship between NAFLD and HCC in patients with prior hepatitis B virus infection. Results: Among HCC patients with both HBsAg and anti-HCV negative, the proportion of prior HBV infection accounted for 86.7%. NAFLD prevalence was higher in patients with HCC based on prior HBV infection than active HBV infection (19.7% vs. 8.5%, P < 0.001). After adjusting for gender, age, hypertension, alanine aminotransferase, and liver cirrhosis, patients with HCC based on prior HBV infection were more likely to develop NAFLD (OR: 2.29, 95% CI: 1.40-3.74), and this phenomenon was observed only in patients with non-cirrhosis (OR: 5.26, 95% CI: 2.53-10.96) and aged≥50 years (OR: 2.36, 95% CI: 1.33-4.20). Conclusion: NAFLD may be a risk factor for HCC in a previously infected patients with HBV, especially in non-cirrhotic and population aged≥50 years.


Subject(s)
Carcinoma, Hepatocellular/epidemiology , Hepatitis B/epidemiology , Hepatitis B Surface Antigens , Hepatitis B virus , Humans , Liver Neoplasms/epidemiology , Middle Aged , Non-alcoholic Fatty Liver Disease/epidemiology , Retrospective Studies , Risk Factors
18.
Chinese Journal of Epidemiology ; (12): 728-733, 2022.
Article in Chinese | WPRIM | ID: wpr-935451

ABSTRACT

Objective: To investigate the type, length, and CG loci of HBV DNA CpG islands in HBsAg positive maternal C genotype and its relationship with intrauterine HBV transmission, so as to provide a new perspective for the study of intrauterine transmission of HBV. Methods: From June 2011 to July 2013, HBsAg-positive mothers and their newborns who delivered in the obstetrics and gynecology department of the Third People's Hospital of Taiyuan were collected. Epidemiological data were collected through face-to-face questionnaires and electronic medical records. Serum HBV markers and serum HBV DNA were detected by electrochemiluminescence and quantitative fluorescence PCR, respectively. Intrauterine transmission of HBV was determined by positive HBsAg and/or HBV DNA in femoral venous blood before injection of HBV vaccine/Hepatitis B immunoglobulin within 24 h of birth. A total of 22 mothers and their newborns with HBV DNA load ≥106 IU/ml in intrauterine transmission were selected as the intrauterine transmission group, and 22 mothers with HBV DNA load ≥106 IU/ml without intrauterine transmission were chosen as the control group by random seed method. The distribution prediction of CpG islands of HBV DNA in 39 mothers with genotype C by HBV DNA sequencing was analyzed. Results: Among 39 mothers with HBV C genotype, 19 were in the intrauterine transmission group, and 20 were in the control group. The HBV DNA of 39 patients with genotype C traditional CpG island Ⅱ and Ⅲ, while the control group had traditional CpG island Ⅰ and novel CpG island Ⅳ and Ⅴ. The length of CpG island Ⅱ and Ⅲ and the number of CG loci of CpG island Ⅱ in the intrauterine transmission group differed from those in the control group (P<0.05). The CpG island Ⅱ length ≥518 bp and the number of CG loci ≥40 in the intrauterine transmission group (11/19) were significantly higher than those in the control group (2/20) (P<0.05). The length of CpG island Ⅱ and the number of CG loci in the X gene promoter region (Xp region) were higher than those in the control group (P<0.05). In the HBV intrauterine transmission group, most of maternal (12/19) HBV DNA CpG island Ⅱ completely covered the Xp region, which was significantly higher than that in the control group (5/20), and the number of HBV DNA Xp region CG loci was higher than that in the control group (P<0.05). Conclusions: The distribution of maternal C genotype HBV DNA CpG islands is related to intrauterine transmission. The length of CpG island Ⅱ and the number of CG sites may increase the risk of intrauterine transmission of HBV.


Subject(s)
Biomarkers , CpG Islands , DNA, Viral/genetics , Female , Hepatitis B , Hepatitis B Surface Antigens , Hepatitis B virus/genetics , Humans , Infant, Newborn , Infectious Disease Transmission, Vertical , Mothers , Pregnancy , Pregnancy Complications, Infectious
19.
Chinese Journal of Epidemiology ; (12): 696-701, 2022.
Article in Chinese | WPRIM | ID: wpr-935446

ABSTRACT

Objective: To study the non/hypo-response to hepatitis B vaccination in HIV-infected patients, identify the influencing factors and provide evidence for the development of hepatitis B prevention and control strategies and measures for special population. Methods: On the basis of the randomized controlled trial of 20 µg hepatitis B vaccine immunization at 0-1-6 month, 0-1-2-6 month and 60 µg hepatitis B vaccine immunization at 0-1-2-6 month, the HIV-infected patients who completed one-month follow-up after the full course vaccination were selected as study subjects. Quantification of antibody to hepatitis B surface antigen (anti-HBs) in serum samples was performed by using chemiluminescent microparticle immunoassay (CMIA) and demographic characteristics, disease history, HIV infection and treatment status of the study subjects were collected. Statistical analysis was conducted by χ2 test, t test, unconditional logistic regression and interaction analyses. Results: The non/hypo-response rates to hepatitis B vaccination were 34.65% (35/101), 24.49% (24/98) and 10.99% (10/91) in 20 µg group at 0-1-6 month or 0-1-2-6 month and 60 µg group at 0-1-2-6 month (P<0.001), respectively. Logistic regression analysis showed that after controlling for confounding factors, the risk for non/hypo-response was 0.22 times higher in HIV-infected patients receiving 60 µg hepatitis B vaccine at 0-1-2-6 month than in patients receiving 20 µg hepatitis B vaccine at 0-1-6 month (95%CI: 0.10-0.50), the risk for non/hypo-response was higher in men than in women (OR=3.65, 95%CI: 1.88-7.07), and the risk for non/hypo-response was 2.64 times higher in those without hepatitis B vaccination history than in those with hepatitis B vaccination history (95%CI: 1.10-6.32). Moreover, there were multiplicative interactions between immunization schedule and gender (OR=2.49, 95%CI: 1.24-5.00). Conclusion: The non/hypo-response rate to hepatitis B vaccination was significantly lower in HIV-infected patients receiving 60 µg hepatitis B vaccine at 0-1-2-6 month than in those receiving 20 µg hepatitis B vaccine at 0-1-6 month and 0-1-2-6 month. Gender, vaccination schedule and history of hepatitis B vaccination were the influencing factors of the non/hypo-response to hepatitis B vaccination. There was a multiplicative interaction between vaccination schedule and gender, and men receiving 20 µg hepatitis B vaccines had a higher risk for non/hypo-response to hepatitis B vaccination.


Subject(s)
Female , Follow-Up Studies , HIV Infections/immunology , Hepatitis B/prevention & control , Hepatitis B Antibodies , Hepatitis B Surface Antigens , Hepatitis B Vaccines/administration & dosage , Humans , Immunization Schedule , Male
20.
Chinese Journal of Epidemiology ; (12): 343-347, 2022.
Article in Chinese | WPRIM | ID: wpr-935393

ABSTRACT

Objective: To analyze the repetitive reporting of hepatitis B in Fujian province during 2016-2020, and provide evidence for the improvement of hepatitis B surveillance. Methods: The reporting cards from the China Information System for Disease Control and Prevention were collected and divided into repetitive reporting cards and non-repetitive reporting cards from the report cards collected according to the valid ID number on the cards, and the proportion of repetitive report cards and related factors were analyzed by using software SAS 9.4. Results: A total of 314 551 hepatitis B reporting cards were submitted in Fujian from 2016 to 2020, in which 90.93% (286 020/314 551) were included in the analysis. The repetitive reporting cards accounted for 10.48% (29 982/286 020). The annual proportion of the repetitive reporting cards from 2016 to 2020 was between 2.98% and 3.71%, showing an overall increasing trend year by year (Z=2.26, P=0.024). The proportions of the repetitive reporting cards in 1-5 years were 3.17%, 5.40%, 7.74%, 9.27% and 10.48%, respectively, showing an increase trend with year (Z=128.16, P<0.001). The proportions of the repetitive reporting cards in 10 areas of Fujian ranged from 5.44% to 13.48% with significant difference (χ2=2 050.41, P<0.001) and increased with the increase of reported incidence of hepatitis B (Z=26.92, P<0.001). There were significant differences in relationships between repetitive reporting proportion and sex, age and type of the cases between the areas with high incidence and low incidence of hepatitis B. Conclusions: The reported incidence of hepatitis B was seriously affected by the repetitive reporting in Fujian from 2016 to 2020. A cross-year and cross-area surveillance mechanism for hepatitis B should be established and targeted measures should be taken to strengthen the control of the repetitive reporting and improve the surveillance for hepatitis B.


Subject(s)
China/epidemiology , Data Collection , Hepatitis B/epidemiology , Humans , Incidence , Software
SELECTION OF CITATIONS
SEARCH DETAIL